Minghui Ji

Discovery of Potent and Wild-Type-Sparing Fourth-Generation EGFR Inhibitors for Treatment of Osimertinib-Resistance NSCLC

Haojie Dong, Xiuquan Ye, Yasheng Zhu et al. · Journal of Medicinal Chemistry · 2023 · 33 citations · Full text

Medicine, Oncology, Pharmacology +13

PTPN2, A Key Predictor of Prognosis for Pancreatic Adenocarcinoma, Significantly Regulates Cell Cycles, Apoptosis, and Metastasis

Wenbin Kuang, Xiao Wang, Jiayu Ding et al. · Frontiers in Immunology · 2022 · 32 citations · Full text

Medicine, Molecular Biology, Oncology +17

Targeting dual-specificity tyrosine phosphorylation-regulated kinase 2 with a highly selective inhibitor for the treatment of prostate cancer

Kai Yuan, Zhaoxing Li, Wenbin Kuang et al. · Nature Communications · 2022 · 18 citations · Full text

Medicine, Oncology, Pharmacology +17

Discovery of novel and orally bioavailable CDK 4/6 inhibitors with high kinome selectivity, low toxicity and long-acting stability for the treatment of multiple myeloma

Kai Yuan, Wenbin Kuang, Weijiao Chen et al. · European Journal of Medicinal Chemistry · 2021 · 17 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +9

Discovery of Dual CDK6/PIM1 Inhibitors with a Novel Structure, High Potency, and Favorable Druggability for the Treatment of Acute Myeloid Leukemia

Kai Yuan, Minghui Ji, Shengnan Xie et al. · Journal of Medicinal Chemistry · 2021 · 16 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17